RecruitingNot ApplicableNCT06681246

The Role of Microbiome in Recurrent Obesity Before and After Antibiotic/Placebo Treatment


Sponsor

Weizmann Institute of Science

Enrollment

200 participants

Start Date

Dec 11, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This past century witnessed a significant increase in the prevalence of obesity. Successful weight loss maintenance is defined as losing at least 10% of the initial body weight and maintaining it for at least one year. However, keeping a low body weight is rarely maintained, as 80% of people who lost 10% of their body weight will return to their initial weight within a year. Although there is no agreement as to what contributes to the recurrent weight regain phenomenon (also known as 'weight cycling' or 'yo-yo diet'), it is strongly associated with the risk of developing metabolic risk factors and their complications, including heart disease and all-cause mortality. Altering the gut microbiota is one method to treat disease states associated with gut bacteria. Antibiotics consumption is known to influence host glycemic response through changes induced in microbiome composition and function. Therefore, it may be a possible pathway to jumpstart changes in the gut microbiota. This study will determine whether microbiome modulation might be a possible future target against recurrent obesity in humans and whether orally administered antibiotic treatment post-weight loss might be an effective intervention to prevent weight regain.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Antibiotic treatment and Placebo for people with obesity and weight loss. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERAntibiotic treatment

10 days of either antibiotics- Augmentin (amoxicillin+clauvonate), 875mg, 2 /day

OTHERPlacebo

consist of a combination of agarose in normal saline/glycerol


Locations(1)

Weizmann Institute of Science

Rehovot, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06681246


Related Trials